Quest reports supportive data for new HDL cholesterol function test

By staff writers

November 15, 2019 -- Quest Diagnostics reported data supporting its new test for high-density lipoprotein (HDL) cholesterol function at the American Heart Association (AHA) annual meeting, ahead of the product's U.S. rollout sometime in 2020.

The assay is a proteomic-based test of cholesterol efflux capacity (CEC), meaning the ability of HDL particles to accept cholesterol from white blood cells and begin the process of reverse cholesterol transport. The test assesses the function of apolipoproteins as a predictor of cholesterol efflux capacity, with results presented in a risk score. It was developed at Cleveland HeartLab, which was acquired by Quest in December 2017.

Data for the test in 341 patients were shared in a poster presentation at the AHA meeting, being held November 16-18 in Philadelphia. The test showed a weak but significant correlation with markers of cardiovascular risk, which suggests it is adding information beyond what is possible with currently available options, the company said in a statement.

"This proteomic approach provides a reproducible high-throughput alternative to traditional cell-based CEC assays," Quest Medical Director Dr. Michael McPhaul and colleagues noted in their poster.

Lab tests show vitamin D, omega-3 fish oil miss health markers
Supplementation with vitamin D and omega-3 fatty acids failed to improve standard lab markers for inflammation and kidney function in two ancillary studies...
Self-testing helps drive demand for bustling HbA1c market
Bruce Carlson, publisher of Kalorama Information, explores factors driving the demand for hemoglobin A1c (HbA1c) testing in people with diabetes, including...
Big data can improve familial hypercholesterolemia screening
A machine-learning algorithm may be useful for scanning electronic health records to spot people with undiagnosed familial hypercholesterolemia based...
Cardiologists back more screening, tight LDL and glucose control
Researchers made a strong call for genetic screening for heterozygous familial hypercholesterolemia at the European Society of Cardiology and World Congress...

Copyright © 2019

Last Updated np 11/15/2019 12:41:11 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.